Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)

Abstract

Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was recently approved for patients with failure to prior NS5A-based treatment. In this German real-world cohort including patients with cirrhosis (27.3 %) and previous decompensation events, 12 weeks of SOF/VEL/VOX resulted in high virologic response rates irrespective of disease severity and prior DAA regimen. Adverse events were mostly mild or moderate and comparable to those seen in the approval studies.

Zusammenfassung

Trotz der hohen Effektivität der direkt antiviralen Therapie der chronischen Hepatitis C kommt es bei einem kleinen Teil der Patienten zu einem fehlenden virologischen Ansprechen auf die zugelassenen Therapieregime. Die Kombinationstherapie aus Voxilaprevir, Velpatasvir, Sofosbuvir wurde kürzlich für die Therapie von Patienten mit Versagen auf eine NS5A-basierte Behandlung zugelassen. In der vorliegenden Deutschen Register-Kohorte wurde bei Patienten einschließlich solcher mit Zirrhose und vorangegangener Dekompensation bei einer Therapie mit VOX/VEL/SOF über 12 Wochen hohe SVR-Raten unabhängig von der Schwere der Erkrankung und vorheriger DAA-Therapien erreicht. Dabei wurden lediglich geringe bis mäßige Nebenwirkungen beobachtet, die sich nicht von denen in den Zulassungsstudien unterschieden.

Key words

hepatitis C virus - real world setting - sustained virological response

Schlüsselwörter

HCV - DAA - Relapse - Dekompensation

^* These authors share senior authorship.

Publikationsverlauf

Eingereicht: 13. Mai 2020

Angenommen: 06. Juli 2020

Artikel online veröffentlicht:
18. September 2020

• References

• 1 World Health Organization (WHO). Global health sector strategy on viral hepatitis, 2016-2021. 2016
• 2 Vermehren J, Park JS, Jacobsen IM. et al. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol 2018; 69: 1178-1187
• 3 Buggisch P, Vermehren J, Mauss S. et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol 2018; 68: 663-671
• 4 Cornberg M, Petersen J, Schober A. et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther 2017; 45: 688-700
• 5 Berg T, Naumann U, Stoehr A. et al. Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry. Aliment Pharmacol Ther 2019; 49: 1052-1059
• 6 Dietz J, Susser S, Vermehren J. et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology 2018; 154: 976-988
• 7 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2016; 66: 153-194
• 8 European Medicines Agency: Vosevi-EMEA/H/C/004350-IB/0020. 2017
• 9 Bourlière M, Gordon SC, Flamm SL. et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017; 376: 2134-2146
• 10 Höner zu Siederdissen C, Maasoumy B, Marra F. et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis 2016; 62: 561-567
• 11 Vermehren J, Peiffer KH, Welsch C. et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2016; 44: 856-865
• 12 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018;
• 13 Degasperi E. et al. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis c patients with previous DAA failure. J Hepatol 2019; 71: 1106-1115
• 14 Llaneras J. et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis c previously treated with DAAs. J Hepatol 2019; 71: 666-672